All In MedTech

Device Trial Radar · NCT03365154

Feasibility Clinical Trial of the Cardio Flow Orbital Atherectomy System to Treat Peripheral Artery Disease (PAD)

Feasibility Clinical Trial of the Cardio Flow FreedomFlow Orbital Atherectomy System to Treat Peripheral Artery Disease

Last checked: Nov 20, 2026Latest source record: May 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

10

Actual

Start

Jan 25, 2018

Primary completion

Feb 22, 2018

Study completion Nov 6, 2018

Sponsor

Lead sponsor
Cardio Flow, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Libra Medical
First posted
Dec 7, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a First in Human early feasibility study of a novel atherectomy device to treat peripheral artery disease. The trial is a prospective, single arm design that will enroll 10 patients at 1 - 2 sites. Patients will be followed at 30 days and 6 months to evaluate vessel patency following treatment. Safety will be assessed by monitoring adverse events throughout the study. Safety and Efficacy will be evaluated by comparing study results to established performance criteria,

Conditions

  • Peripheral Arterial Disease

Interventions

  • Cardio Flow FreedomFlow™ Orbital Atherectomy System treatmentDevice

    Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.

  • Balloon AngioplastyDevice

    Low pressure balloon angioplasty may be used following atherectomy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Treated Lesions With Achievement of ≤ 50% Residual Stenosis Without Adjunctive TherapyTime frame: At time of procedure
  2. Number of Participants Who Were Free From New-onset Major Adverse Events at 30 Days Post-treatmentTime frame: 30 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cardiovascular Research of North Florida, LLC

    Gainesville, Florida

  • Eastlake Cardiovascular, PC

    Saint Clair Shores, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.